Home › Crohn's Disease › NCT06647615
A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease
Recruiting
Who can join
Ages 18 to 70 · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients with a diagnosis of endoscopically and histologically confirmed CD with evidence of C-reactive protein \< 5 mg/dL and fecal calprotectin \< 150microg/g who also report any abdominal pain at least weekly will be included. Exclusion Criteria: * Patients will be excluded from the study if they do not have biopsy-proven CD, have a known seizure disorder, if symptoms are thought to represent an organic disorder, those with visual or hearing impairments, if symptoms represent a known pelvic floor disorder, if the patient is using opioids, has significant ongoing psychological distress (HAD score \> 11 for either anxiety or depression), or if the patient can not actively participate in the study for any other reason (e.g., inability to understand English as the VR program as an English only).
About the study
The purpose of this research is to see if patients with Crohn's disease (CD) and abdominal pain resulting in health-related quality of life deficits despite lack of evidence of active inflammation improve with the use of virtual reality (VR).
What is being tested
- VR headset (device)
Sponsor: Mayo Clinic · Participants: 15 · Started: May 24, 2024
Contact the study team
- Lauren P Loeb, MD · Phone: 904-953-6970
Official record on ClinicalTrials.gov — NCT06647615
Locations in the U.S.
| Florida | Mayo Clinic Florida, Jacksonville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.